A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis

Main Article Content

Brandon Kirsch
Kirsch Dermatology, Naples, FL

Janet Dubois
DermResearch Inc., Austin, TX

Martin Zaiac
Sweet Hope Research Specialty, Hialeah, FL

Sanjeev Ahuja
Former CMO, Brickell Biotech, Inc., Boulder, CO

Deepak Chadha
Brickell Biotech, Inc., Boulder, CO

Keywords

Hyperhidrosis, Sofpironium Bromide, Topical, Pediatrics, Adolescents, Safety, Tolerability, Pharmacokinetics

Abstract

Abstract not available.

References

1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis; an update on prevalence and
severity in the United States. Arch Dermatol Res. 2016; 308:743-749.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.116

Article Details

How to Cite
Kirsch, B., Dubois, J., Zaiac, M., Ahuja, S., & Chadha, D. (2020). A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis. SKIN The Journal of Cutaneous Medicine, 4(6), s116. https://doi.org/10.25251/skin.4.supp.116
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Hyperhidrosis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 > >>